The European biosimilar market was valued at $11.85 billion in 2023 and is projected to grow to $53.22 billion by 2032, reflecting a CAGR of 17.6% from 2024 to 2032. Key drivers of this growth include the adoption of favorable reimbursement policies to promote biosimilar use, the expansion of production facilities to ensure a stable product supply, and ongoing technological advancements. https://www.imarcgroup.com/europe-biosimilar-market